September 15, 2025 — Taipei, Taiwan Glac Biotech, a Taiwan-based developer of probiotics and postbiotics, announced that its core probiotic strain CP-9 (Bifidobacterium lactis CCTCC M 2014588) has been approved with Generally Recognized as Safe (GRAS) status by the U.S. Food and Drug Administration (FDA). This approval allows CP-9 to be used in a wide range of food and beverage products, including sports drinks, fortified waters, cereals, dairy and non-dairy items, nutrition bars, candies, fruit juices, soy and plant-based protein products, and infant foods. The approval at levels up to 10⁹ CFUs per serving expands access to probiotic-enriched foods across age groups and dietary preferences.
Science Significance
CP-9 has been extensively studied for its beneficial effects on gut microbiota balance and immune system support. It plays a crucial role in helping maintain healthy digestion and enhancing the body’s natural defenses. Research shows that probiotic strains like CP-9 can reduce inflammation, improve nutrient absorption, and strengthen the gut barrier against harmful pathogens. The strain’s recognition at the 2023 NutraIngredients Awards highlights its emerging role in preventive health. It is particularly promising for use in functional foods aimed at improving everyday well-being. Additionally, its inclusion in infant formulas supports early development of the gut microbiome, which is essential for long-term health.
Regulatory Significance
The FDA’s GRAS approval for CP-9 confirms that the strain meets rigorous scientific standards for safety. Unlike novel food ingredients that require full approval, GRAS designation allows ingredients already backed by scientific evidence to be integrated into products more efficiently. This regulatory milestone demonstrates the FDA’s confidence in the scientific data provided by Glac Biotech, including preclinical and clinical studies supporting safety, dosage, and efficacy. The approval process emphasizes that probiotic strains, while widely used, must still be evaluated to protect public health. The designation also provides clarity for manufacturers, ensuring compliance with U.S. food safety laws while promoting innovation in the food industry.
Business Significance
Advertisement
For Glac Biotech, securing GRAS status for CP-9 is a strategic achievement that strengthens its market presence globally. The strain builds on the success of its earlier product, MP108, approved in 2023 as the first probiotic strain in Asia recognized for infant use. With rising consumer demand for health-focused foods, the addition of CP-9 allows manufacturers to create products with scientifically supported claims. The growing interest in immune health, digestive wellness, and functional nutrition places Glac Biotech in a position to expand into new markets and partner with global food and beverage brands. The ability to incorporate CP-9 into everyday products—from snacks to beverages—offers manufacturers a competitive edge by aligning with wellness trends and consumer preferences for clean-label and natural ingredients.
Patients’ Significance
The approval of CP-9 gives consumers access to probiotic products that can support a healthy gut and immune system. Individuals looking for convenient ways to boost wellness can now choose from a variety of foods containing CP-9, without the need for supplements or complex formulations. For parents, CP-9’s approval for use in infant foods ensures that children’s gut health is supported from the earliest stages of life. Probiotics play a key role in establishing healthy digestion and strengthening the immune system, both of which are vital during infancy. For adults, especially those with irregular diets, stress, or digestive discomfort, CP-9 offers a daily wellness option that is easily integrated into meals and snacks. This helps improve nutrient absorption, promote bowel health, and support overall well-being.
Policy Significance
The GRAS designation of CP-9 highlights the need for regulatory frameworks that balance innovation with safety. As food technologies evolve, agencies like the FDA must continuously update guidelines to accommodate new ingredients while maintaining public trust. Clear scientific standards and transparent evaluation processes are essential for promoting consumer confidence in functional foods. Regulatory clarity not only protects consumers but also encourages research, investment, and responsible product development. Moreover, this approval demonstrates how science-driven policymaking can pave the way for global health advancements while supporting industry growth.
The GRAS approval of CP-9 signals a promising future for probiotics in food and nutrition. With more scientific evidence supporting their health benefits, probiotics are expected to become key components of modern diets worldwide. As consumer awareness grows, functional foods fortified with probiotic strains like CP-9 will likely play a larger role in preventive health care. This trend will encourage further research into personalized nutrition and targeted health solutions. Glac Biotech’s success with CP-9 marks a pivotal moment in the industry, combining scientific innovation, regulatory compliance, and market demand to deliver accessible health solutions for all.
Source: Glac Biotech Press Release
